tradingkey.logo

PAVmed Inc

PAVM
10.800USD
+0.220+2.08%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
8.30MMarktkapitalisierung
VerlustKGV TTM

PAVmed Inc

10.800
+0.220+2.08%

mehr Informationen über PAVmed Inc Unternehmen

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

PAVmed Inc Informationen

BörsenkürzelPAVM
Name des UnternehmensPAVmed Inc
IPO-datumJul 27, 2016
CEOAklog (Lishan)
Anzahl der mitarbeiter39
WertpapierartOrdinary Share
GeschäftsjahresendeJul 27
Addresse360 Madison Avenue
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10017
Telefon12129494319
Websitehttps://pavmed.com/
BörsenkürzelPAVM
IPO-datumJul 27, 2016
CEOAklog (Lishan)

Führungskräfte von PAVmed Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.62K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
7.56K
-166.00%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
7.17K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
5.41K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.62K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
7.56K
-166.00%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
7.17K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
5.41K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
8.62%
Sargent Investment Group, LLC
3.37%
First Manhattan Co. LLC
2.39%
Dubreville (Anthony Michael)
2.03%
The Vanguard Group, Inc.
1.15%
Andere
82.45%
Aktionäre
Aktionäre
Anteil
Tasso Partners, LLC
8.62%
Sargent Investment Group, LLC
3.37%
First Manhattan Co. LLC
2.39%
Dubreville (Anthony Michael)
2.03%
The Vanguard Group, Inc.
1.15%
Andere
82.45%
Aktionärstypen
Aktionäre
Anteil
Corporation
9.62%
Investment Advisor
8.36%
Individual Investor
7.99%
Research Firm
0.65%
Investment Advisor/Hedge Fund
0.55%
Hedge Fund
0.34%
Venture Capital
0.04%
Andere
72.45%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
60
96.72K
9.71%
+34.80K
2025Q3
89
2.39M
8.50%
+565.99K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tasso Partners, LLC
85.81K
8.62%
+85.81K
--
Feb 21, 2025
Sargent Investment Group, LLC
33.54K
3.37%
+33.54K
--
Jul 01, 2025
First Manhattan Co. LLC
23.80K
2.39%
--
--
Sep 30, 2025
Dubreville (Anthony Michael)
20.21K
2.03%
+20.21K
--
Aug 30, 2024
The Vanguard Group, Inc.
6.95K
0.7%
+4.23K
+155.74%
Sep 30, 2025
Pavilion Venture Partners, L.L.C.
9.90K
0.99%
--
--
Oct 23, 2025
Aklog (Lishan)
7.62K
0.77%
--
--
Oct 23, 2025
Glennon (Michael J)
7.56K
0.76%
-166.00
-2.15%
Oct 23, 2025
White (Debra Jayne)
7.17K
0.72%
--
--
Oct 23, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
KeyAI